Clinical Trial Update: Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating an antigen-specific T cell therapy for patients with acute myeloid leukemia or myelodysplastic syndrome relapsed after all…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Antigen-specific T cell therapy

Snippet

Sponsor: NexImmune Inc. | Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1, Phase 2 | Status: UNKNOWN